🇺🇸 FDA
Patent

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

granted A61KA61K31/519A61K39/3955

Quick answer

US patent 10729768 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) held by TG Therapeutics, Inc. expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TG Therapeutics, Inc.
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K31/519, A61K39/3955, A61K45/06, A61P